SCHEMBL2033004

SCHEMBL2033004

CCC(CC)C(c1ccc([N+](=O)[O-])cc1)P(=O)(O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.46
CA12 O43570 3/20 0.46
MMP2 P08253 3/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
MMP14 P50281 1/20 0.46
ALDH1A1 P00352 4/20 0.45
MAPT P10636 3/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CA2 P00918 4/20 0.43
CA9 Q16790 2/20 0.43
CA14 Q9ULX7 2/20 0.43
KDM4E B2RXH2 1/20 0.43
AKR1C3 P42330 1/20 0.43
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
NPC1 O15118 1/20 0.42
GRM8 O00222 1/20 0.42
GRM6 O15303 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2127924 1.00 CA1 (0.46) CA1CA12MMP2MMP9MMP8
SCHEMBL2031318 0.77 ANPEP (0.38) ALDH1A1MAPTKDM4EGRM8GRM4
SCHEMBL14040086 0.76 NPC1 (0.49) ALDH1A1MAPTMEN1KMT2AKDM4E
SCHEMBL1542690 0.76 SRC (0.50)
SCHEMBL3182640 0.75 CA12 (0.53) CA1CA12MMP2MMP9MMP8
SCHEMBL2421098 0.75 CA12 (0.53) CA1CA12MMP2MMP9MMP8
SCHEMBL16931022 0.74 ACP3 (0.63) CA1CA12MMP2MMP9MMP8
SCHEMBL3230188 0.73 CA12 (0.51) CA1CA12MMP2MMP9MMP8
SCHEMBL3920417 0.73 ALDH1A1 (0.68) ALDH1A1MAPTMEN1KMT2AKDM4E
SCHEMBL3920418 0.73 ALDH1A1 (0.68) ALDH1A1MAPTMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399433-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2013-03-19 US disclosed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP disclosed
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS DPYD, PTK2, TYMS CA1 4413/4885CA12 4611/4885MMP2 4375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.